- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04877444
Exercise Primed Stroke Rehabilitation
Priming the Rehabilitation Engine: Aerobic Exercise as the Fuel to Spark Behavioral Improvements in Stroke
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The purpose of this project is to examine the 'priming' effect of aerobic exercise (AEx) on a motor rehabilitation intervention for chronic stroke survivors. Aerobic exercise (AEx) promotes numerous functional, cognitive, and psychological benefits. For example, AEx has demonstrated positive effects on physical performance, cardiovascular health, global cognition, executive function and depressive symptoms in neurologically healthy individuals as well as survivors of stroke. Importantly, emerging evidence also supports the use of AEx as a priming tool to enhance motor outcomes following targeted rehabilitation. Potential mechanisms underlying the priming effects of AEx include increases in circulating brain-derived neurotrophic factor (BDNF) and corticomotor excitability (CME). The wide-ranging behavioral and physiological benefits of AEx ideally suit it to serve as an adjunctive primer to stroke rehabilitation programs. The investigators' conceptual framework involves priming with AEx prior to targeted motor rehabilitation to enhance the 'neuroplastic environment" and make the brain more amenable to adaptation, thereby enhancing response to rehabilitation. Specifically, the investigators propose to pair AEx with an upper extremity virtual reality rehabilitation game called Duck Duck Punch (DDP) as the platform for examining the adjunctive potential of AEx. To evaluate the priming effects of AEx, chronic stroke survivors will be randomly assigned to receive 8 weeks (3 sessions/week) of DDP preceded by either 15 minutes of AEx (AEx+DDP) or a stretching control (CON+DDP). This design will address the following specific aims:
Aim 1: Evaluate the priming effects of AEx on a motor rehabilitation intervention for chronic stroke survivors.
Aim 2: Quantify the effects of AEx priming on biomarkers of neuroplasticity.
By stimulating the neuroplastic environment the investigators aim to enhance the response to motor rehabilitation. However, additional stroke sequelae (eg. cognitive and psychological function) may influence the magnitude of change in motor function. Depression and impaired cognitive function can negatively influence stroke recovery outcomes, and are characterized by reduced neuroplastic potential and BDNF. Subsequently, subjects with depression or cognitive impairment are often excluded from rehabilitation trials. Thus, data that describes the relationship of multiple domains of stroke recovery as well as the neurobiological underpinnings of the response to rehabilitation will illuminate this gap in the literature and generate the formation of new hypotheses for future study.
Exploratory Aim: Examine the influence of cognitive and psychological function on motor response to AEx+DDP.
The primary goal of this proposal is to provide foundational support to develop AEx as an adjunctive primer to rehabilitation. The data generated will inform the development of additional AEx-based interventions for individuals following stroke as well as other neurological or neuropsychiatric conditions.
Study Type
Enrollment (Estimated)
Phase
- Early Phase 1
Contacts and Locations
Study Contact
- Name: Ryan E Ross, PhD
- Phone Number: (843) 792-3477
- Email: Ryan.Ross2@va.gov
Study Locations
-
-
South Carolina
-
Charleston, South Carolina, United States, 29401-5703
- Recruiting
- Ralph H. Johnson VA Medical Center, Charleston, SC
-
Contact:
- Ryan E Ross, PhD
- Phone Number: 843-792-3477
- Email: Ryan.Ross2@va.gov
-
Principal Investigator:
- Ryan E Ross, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- experienced unilateral stroke at least 6 months prior;
- voluntarily shoulder flexion of the affected arm 20 degrees with simultaneous elbow extension 10 degrees;
- moderate arm movement impairment (UE Fugl-Meyer Assessment > 21 but < 52 points;
- passive range of motion in paretic shoulder, elbow, wrist, thumb and fingers within 20 degrees of normal;
- 50-90 years of age;
- ability to communicate as per the therapists' judgement at baseline testing;
- ability to complete and pass an exercise tolerance test; 8) Box & Block test score of at least 3 blocks in 60 seconds with the affected arm.
Exclusion Criteria:
- lesion in brainstem/cerebellum as these may interfere with visual-perceptual/cognitive skills needed for motor re-learning;
- presence of other neurological disease that may impair motor learning skills;
- orthopedic condition or impaired corrected vision that alters reaching ability (e.g., prior rotator cuff tear without full recovery);
- paretic arm pain that interferes with reaching;
- unable to understand or follow 3-step directions;
- severe cognitive impairment (MoCA score 17);
- severe aphasia;
- inability to read English,
- history of congestive heart failure, unstable cardiac arrhythmias, hypertrophic cardiomyopathy, severe aortic stenosis, angina or dyspnea at rest or during ADL's;
- Severe hypertension with systolic >200 mmHg and diastolic >110 mmHg at rest;
- History of COPD or oxygen dependence;
- History of DVT or pulmonary embolism within 6 months;
- Uncontrolled diabetes with recent weight loss, diabetic coma, or frequent insulin reactions;
- UBACC score < 15; and for brain stimulation procedures only:
- electronic or metallic implants;
- history of seizures;
- women of child bearing potential.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Aerobic exercise (AEx) + upper extremity rehabilitation
Subject will receive a total of 24 intervention sessions.
In each session, subjects will perform 15 minutes of AEx followed by 200 repetitions of an upper extremity rehabilitation program.
|
Duck Duck Punch (DDP) is an interactive computer game deliberately designed to enhance UE movement quality via individualized progressive movement practice.
DDP is unique as it uses Microsoft Kinect skeletal tracking technology to assess movement performance.
The participant sits in front of the Microsoft Kinect and controls a virtual arm with his/her physical arm; reaching forward to "punch" virtual ducks.
The goal 'dose' of DDP will be 200 repetitions.
Other Names:
Subjects will perform 15 minutes of aerobic exercise on a recumbent stationary cycle.
The target intensity of aerobic exercise is 70% heart rate reserve.
Following aerobic exercise subject will play an upper extremity rehabilitation game called Duck Duck Punch.
Other Names:
|
Experimental: Stretching (CON) + upper extremity rehabilitation
Subjects will perform 15 minutes of lower extremity stretching.
Following lower extremity stretching subjects will receive 200 repetitions of DDP.
|
Duck Duck Punch (DDP) is an interactive computer game deliberately designed to enhance UE movement quality via individualized progressive movement practice.
DDP is unique as it uses Microsoft Kinect skeletal tracking technology to assess movement performance.
The participant sits in front of the Microsoft Kinect and controls a virtual arm with his/her physical arm; reaching forward to "punch" virtual ducks.
The goal 'dose' of DDP will be 200 repetitions.
Other Names:
Subjects will perform 15 minutes of lower extremity stretching.
Following aerobic exercise subject will play an upper extremity rehabilitation game called Duck Duck Punch.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline upper extremity impairment assessed by the Fugl Meyer Upper Extremity Assessment (FMA-UE)
Time Frame: Approximately 8 weeks
|
The FMA-UE is a 33-item measure of UE impairment; however, the 3 items testing reflex response will not be administered because they do not measure a voluntary movement construct.
Each item will be scored on a 3-point rating scale (0=unable, 1=partial 2=near normal performance), item ratings will be summed and reported out of 60 points so that larger numbers indicate greater UE motor ability.
|
Approximately 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline upper extremity motor function assessed by the Wolf Motor Function Test (WMFT)
Time Frame: Approximately 8 weeks
|
The WMFT is a 15-item measure of upper extremity functional ability.
Performance of each item will be timed (seconds) and the average time to perform items will be reported so that lower values indicate greater upper extremity function.
|
Approximately 8 weeks
|
Change from baseline locomotor function assessed by self-selected walking (SSWS) speed and six-minute walk test (6MWT)
Time Frame: Approximately 8 weeks
|
Locomotor function will be assessed with SSWS and the 6MWT.
For SSWS, subjects will walk on a 14 ft.
long gait mat (GaitRite).
For 6MWT subjects will walk in an unobstructed hallway for six minutes.
These assessments will provide measures of mobility and functional capacity.
|
Approximately 8 weeks
|
Change from baseline health related quality of life assessed by the Stroke Impact Scale (SIS)
Time Frame: Approximately 8 weeks
|
The SIS assesses physical function as well as other dimension of health-related quality of life: emotion, communication, memory & thinking, and social role function.
Specifically, the Hand and Perceived Recovery subsets of the SIS will be used to assess the effect of the intervention on 'real world' arm use.
The SIS-hand consists of 5-items regarding difficulty of paretic hand use during everyday tasks during the previous two weeks.
Items will be rated on a 5-point scale (5=not difficult, 1=cannot do) and reported as an average item rating.
The SIS-recovery subtest is a single-item in which the participant rates his/her perceived post-stroke recovery from 0%-100% recovered.
|
Approximately 8 weeks
|
Change from baseline depressive symptoms assessed by the Geriatric Depression Scale (GDS)
Time Frame: Approximately 8 weeks
|
The GDS-short form is a 15-item self-report questionnaire that assesses the presence of depressive symptomology in elderly individuals.
Questions are in yes/no format with a maximum score of.
Scores greater than 5 indicate probable depression.
This assessment will provide information regarding the presence of depressive of symptoms and the potential impact such symptoms may have on response to the proposed intervention.
|
Approximately 8 weeks
|
Change from baseline cognitive function assessed by National Institutes of Health Toolbox - Cognition Battery (NIHTB-CB)
Time Frame: Approximately 8 weeks
|
The NIHTB-CB is a brief (~30 minutes) and comprehensive evaluation of multiple domains of cognitive function including executive function, working memory, episodic memory, processing speed, and language.
There are seven subtests (picture vocabulary, oral reading recognition, picture sequence memory test, pattern comparison, list sorting, flanker, dimensional change card sort) within the NIHTB, which can be used to generate composite scores in fluid and crystallized cognitive function.
This provides an opportunity to gain objective insight into granular and global changes in cognitive function.
The NIHTB-CB has been validated in stroke.4
|
Approximately 8 weeks
|
Change from baseline peripheral plasma and serum brain-derived neurotrophic factor (BDNF)
Time Frame: Approximately 8 weeks
|
Blood specimens will be obtained immediately before and after AEx or CON on three separate occasions (intervention sessions 1, 13, and 24).
Briefly, an intravenous catheter will be placed in a superficial forearm vein at the beginning of the priming session and will be maintained patent using an isotonic saline solution.
Baseline blood samples will be drawn immediately before the priming session (AEx or CON) commences.
Immediate post-AEx or CON, blood samples will be taken within sixty seconds of priming session completion while the participant remains seated in the cycle ergometer.
|
Approximately 8 weeks
|
Change from baseline neuroplastic potential
Time Frame: Approximately 8 weeks
|
Subjects will have neuroplastic potential assessed with a plasticity-inducing paradigm called paired associative stimulation (PAS).
Briefly, PAS utilizes a repeated and timed peripheral nerve stimulation combined with transcranial magnetic stimulation (TMS) of the contralateral motor cortex to induce motor cortex plasticity.
Prior to- and after PAS, motor cortex plasticity will be assessed via motor evoked potentials (MEP) which are obtained by single pulse TMS and electromyography (EMG) of the contralateral abductor pollicis brevis muscle.
The relative change in mean peak-to-peak amplitude (measured in millivolts) of twenty MEP's obtained prior to PAS and following PAS will be used as the index of neuroplastic potential.
The change in this index 8 weeks from baseline will indicate changes in neuroplastic potential.
|
Approximately 8 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Ryan E Ross, PhD, Ralph H. Johnson VA Medical Center, Charleston, SC
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- B3540-W
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke
-
University Hospital, GhentRecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Stroke HemorrhagicBelgium
-
Moleac Pte Ltd.RecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, CryptogenicSingapore, Philippines
-
Moleac Pte Ltd.Not yet recruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, Cryptogenic
-
IRCCS San Camillo, Venezia, ItalyRecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke HemorrhagicItaly
-
Vanderbilt University Medical CenterPatient-Centered Outcomes Research Institute; University of Alabama at BirminghamEnrolling by invitationStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Engagement, Patient | Stroke HemorrhagicUnited States
-
University of MinnesotaAmerican Occupational Therapy FoundationRecruitingStroke | Stroke Sequelae | Stroke Hemorrhagic | Stroke IschemicUnited States
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Michael Smith Foundation for...RecruitingStroke | Stroke, Ischemic | Stroke Hemorrhagic | Chronic StrokeCanada
-
University of CincinnatiMedical University of South Carolina; University of California, Los Angeles; University...RecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke HemorrhagicUnited States
-
Turkish Stroke Research and Clinical Trials NetworkElectroCore INC; Turkish Neurological SocietyCompletedStroke | Stroke, Ischemic | Stroke, Acute | Stroke, HemorrhagicTurkey
-
University of LiegeCompletedStroke, Acute | Stroke Hemorrhagic | Stroke, ComplicationBelgium
Clinical Trials on Duck Duck Punch
-
Medical University of South CarolinaCompleted
-
Medical University of South CarolinaNational Institute of Neurological Disorders and Stroke (NINDS); National Institutes...CompletedStroke | Rehabilitation | Recovery of FunctionUnited States
-
Emory UniversityAmerican Family Life Assurance Company (Aflac Inc.)CompletedPediatric CancerUnited States
-
M.D. Anderson Cancer CenterUnited States Department of DefenseCompletedMelanoma | Sarcoma | Breast Cancer | Malignant Female Reproductive System Neoplasm | Genitourinary CancerUnited States
-
Maastricht University Medical CenterCompletedBasal Cell CarcinomaNetherlands
-
Tampere University HospitalOlfactomics OyRecruitingOral Squamous Cell CarcinomaFinland
-
Tampere University HospitalOlfactomics OyRecruiting
-
Ohio State UniversityActive, not recruitingCellulitis | PseudocellulitisUnited States
-
Nova Scotia Health AuthorityUnknown
-
Duke UniversityTerminated